- Companies
- Atia Vision
Atia Vision Funding, Investors & Competitors
Atia Vision has raised $111M across 7 funding rounds, most recently a $29M undisclosed-stage round in August 2022.
Last Atia Vision funding round
$29M
Undisclosed stage · Aug 2022
Cumulative funding Atia Vision raised
$111M
across 7 funding rounds
Key investors in Atia Vision
Cormorant Asset Management
The Capital Partnership
AMED Ventures
Medvance Incubator Partners
Rising Tide
Delos Capital
Shangbay Capital
Picard Angst MedTech Fund
About Atia Vision
Atia Vision is a medical device developer focused on intraocular lenses for cataract and presbyopia treatment. Headquartered in Campbell, California since 2012, it engineers a modular accommodating intraocular lens with a dynamic base responsive to ciliary muscles and a fixed optic for postoperative adjustments. This technology restores near, intermediate, and distance vision for patients undergoing surgery, advancing ophthalmic solutions toward extended-focus capabilities in the United States and international markets.
Founded
2012
HQ
Website
Status
Privately held
Customer focus
B2B
Revenue model
Product sales, Subscription
Atia Vision Funding History
Atia Vision has raised a total of $111M across 7 funding rounds.
Atia Vision's first fundraising round was a $3M Series B in May 2015. The most recent completed round was a $29M undisclosed-stage round in August 2022.
Atia Vision funding rounds
| Date | Stage | Investors | Raised | Deal Summary |
|---|---|---|---|---|
| Aug 2022 | Undisclosed stage | - | $29M | Atia Vision, Inc., a Shifamed portfolio company, develops a modular presbyopia-correcting intraocular lens (IOL) technology, specifically the OmniVu™ Lens System, aimed at improving outcomes for patients with cataracts and presbyopia. The company announced the first close of a $42M Series E financing on August 2, 2022, led by Cormorant Asset Management, with participation from The Capital Partnership (TCP), PA MedTech VC Fund, AMED Ventures, and Shifamed angel investors. Funds are designated to expand the clinical program, scale manufacturing capabilities, and grow the team. Atia Vision's revenue model involves selling its proprietary IOLs directly to ophthalmic surgeons and healthcare facilities for cataract surgeries, fostering direct relationships with medical institutions. The company, founded by Claudio Argento and led by CEO Mariam Maghribi, targets markets with high cataract surgery demand and plans post-funding expansions into new products, geographic markets, and team strengthening. Subsequent developments include presenting first-in-human clinical data for the OmniVu IOL at the 2023 ASCRS Annual Meeting, advancing toward potential market entry in ophthalmology segments affected by visual impairment from cataracts and presbyopia. |
| Aug 2022 | Series E | Cormorant Asset Management (lead); Picard Angst MedTech Fund; The Capital Partnership; AMED Ventures | $42M | Atia Vision is a Shifamed portfolio company developing a modular presbyopia-correcting intraocular lens (IOL) implanted using conventional cataract techniques, featuring a shape-changing, fluid-filled base with an exchangeable fixed power front optic to provide dynamic power response for clear vision from far to near, addressing limitations of current solutions for cataracts and presbyopia patients. The Series E financing, first close announced around August 2, 2022, raised $42.18M led by Cormorant Asset Management, with participation from AMED Ventures, Picard Angst MedTech Fund, The Capital Partnership, Shifamed angel investors, and undisclosed angel investors; some sources report $28.65M raised in this round. Funds are allocated to expand the clinical program, scale manufacturing capabilities, and grow the team. The company, founded in 2012 in Campbell, CA, focuses on innovative IOLs like the OmniVu Lens System sold to ophthalmic surgeons and facilities, targeting high cataract surgery markets with plans for geographic expansion post-funding. |
| Nov 2021 | Series A | - | $5M | Atia Vision is a medical device company developing a modular presbyopia-correcting intraocular lens (IOL) technology to improve patient outcomes in cataracts and presbyopia treatment. Formed by Shifamed LLC, the company focuses on advancing its clinical program and scaling manufacturing capabilities. On August 2, 2022, Atia Vision closed its Series E funding round, raising $42.18M led by Cormorant Asset Management, with participation from The Capital Partnership, PA MedTech VC Fund (AMED Ventures), and Shifamed angel investors. Funds from this round support clinical expansion, manufacturing scale-up, and team growth. The company has raised a total of $90.17M across 9 or 10 rounds from 8 investors, including Shifamed. |
| May 2019 | Series D | Cormorant Asset Management (lead); Shangbay Capital; The Capital Partnership; AMED Ventures | $20M | Atia Vision, a Shifamed portfolio company based in Campbell, California, developed a modular presbyopia-correcting accommodating intraocular lens technology designed to address the unmet needs of cataract and presbyopia patients. The company's innovation features an accommodating base responsive to ciliary muscles that simulates the natural mechanism of the eye, combined with a fixed lens element allowing for subsequent refractive correction, enabling patients to restore a full range of functional vision through a conventional cataract procedure. In May 2019, Atia Vision closed two tranches of Series D financing totaling $40 million, led by Cormorant Asset Management with participation from The Capital Partnership (TCP), AMED Ventures, and Shangbay Capital. The first tranche of $20 million closed on May 2, 2019, and was followed by a second tranche of $20 million on May 19, 2019. The company stated that financing proceeds would be used to advance clinical efforts, expand early clinical experience treating cataract patients, support expansion of Atia Vision's facility, and implement product improvements based on early clinical evidence demonstrating accommodation. As of 2022, Atia Vision had raised a Series E round of $42.18 million, indicating continued investor confidence in the company's technology platform and clinical progress. |
| Dec 2018 | Series C | The Capital Partnership (lead); Medvance Incubator Partners; Cormorant Asset Management | $10M | Atia Vision develops innovative intraocular lenses (IOLs) to enhance vision for cataract patients, focusing on dual-optic presbyopia-correcting technology. The company has raised a total of $90.17M across 9 funding rounds, with investors including Cormorant Asset Management, The Capital Partnership, AMED Ventures, and Shifamed. A Series C investment of $10M is noted in 2018, aligning with the specified investors and approximate date. Later rounds include a $20M Series D in May 2019 led by Cormorant with participation from The Capital Partnership, and a Series E of $42.18M in August 2022. Funds from these rounds support clinical programs, manufacturing expansion, and team growth. Atia Vision has advanced design verification, biocompatibility testing, first-in-human studies, and quality systems ahead of commercialization. |
| Mar 2018 | Seed | - | $2M | - |
| May 2015 | Series B | Medvance Incubator Partners (lead); Delos Capital; Rising Tide | $3M | Atia Vision, a stealth-mode medical device company spun out from Shifamed, raised $3 million in the first tranche of a $5 million Series B round on May 11, 2015, led by Medvance Incubator Partners with participation from Delos Capital and Rising Tide. The funding supported early development of its technology. Atia Vision develops intraocular lenses to address vision impairments like cataracts and presbyopia. |
Who has invested in Atia Vision?
8 investors have backed Atia Vision across its funding rounds, including Cormorant Asset Management, The Capital Partnership, AMED Ventures, Medvance Incubator Partners, Rising Tide and Delos Capital.
Lead investors include Cormorant Asset Management, The Capital Partnership and Medvance Incubator Partners.
Atia Vision Investors
| Investor | HQ | Rounds | Role | First check |
|---|---|---|---|---|
| 3 | Lead | Dec 2018 | ||
| 3 | Lead | Dec 2018 | ||
| 2 | Lead | May 2015 | ||
| 2 | Participant | May 2019 | ||
| 1 | Participant | Aug 2022 | ||
| 1 | Participant | May 2019 | ||
This data is available for Pro users. Sign up to see all 8 Atia Vision investors. Start Free Trial | ||||
Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples
Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.
Start Free TrialAtia Vision Competitors
Atia Vision competitors include listed companies like IDEXX Laboratories, GE HealthCare, United Imaging and Glaukos, and private ones like Dental Monitoring and AcuityMD.
| Company | HQ | Status | Revenue | EBITDA | Valuation | Revenue Multiple |
|---|---|---|---|---|---|---|
| Publicly listed | $4.3B | $1.5B | $40B | 8.9x | ||
| Publicly listed | $21B | $3.7B | $29B | 1.8x | ||
| Publicly listed | $2.1B | $367M | $12B | 4.8x | ||
| Publicly listed | $507M | ($157M) | $9.5B | 14.6x | ||
| Private | $91M | - | $1B | - | ||
| Private | - | - | $955M | - |
Atia Vision Public Comps
Atia Vision is still privately-owned, but its public comps include Samsung, Johnson & Johnson, Roche, Thermo Fisher Scientific, Siemens, Abbott, Danaher, Intuitive Surgical, Medtronic and Stryker.
| Last FY | EV/Revenue | EV/EBITDA | ||||||
|---|---|---|---|---|---|---|---|---|
| Revenue | EBITDA | Last FY | LTM | 2027E | Last FY | LTM | 2027E | |
| $243B | $67B | 4.4x | 2.4x | 15.8x | 4.4x | |||
| $94B | $40B | 7.2x | 6.8x | 17.0x | 18.3x | |||
| $77B | $26B | 5.0x | 4.9x | 14.6x | 12.4x | |||
| $45B | $11B | 6.3x | 6.0x | 26.8x | 23.6x | |||
| $91B | $15B | 3.0x | 2.9x | 18.1x | 15.7x | |||
| $44B | $12B | 4.6x | 4.2x | 17.4x | 15.8x | |||
| $25B | $6.9B | 7.0x | 6.6x | 24.8x | 21.1x | |||
| $10B | $3.6B | 13.0x | 11.6x | 36.6x | 25.7x | |||
This data is available for Pro users. Sign up to see all Atia Vision competitors and their valuation data. Start Free Trial | ||||||||
Common questions about Atia Vision
| When was Atia Vision founded? | Atia Vision was founded in 2012. |
| Where is Atia Vision headquartered? | Atia Vision is headquartered in San Jose, CA, United States. |
| Is Atia Vision publicly listed? | No, Atia Vision is a private, VC-backed company. |
| How much funding has Atia Vision raised? | Atia Vision has raised $111M across 7 funding rounds. |
| What was Atia Vision's last funding round? | Atia Vision's last funding round was a $29M undisclosed-stage round in August 2022. |
| Who are Atia Vision's investors? | Atia Vision's investors include The Capital Partnership, Cormorant Asset Management, Medvance Incubator Partners, AMED Ventures, Picard Angst MedTech Fund, Shangbay Capital, Delos Capital and Rising Tide. |
| Which companies are comparable to Atia Vision? | Companies comparable to Atia Vision include IDEXX Laboratories, GE HealthCare, United Imaging, Glaukos, Dental Monitoring and AcuityMD. |
See companies similar to Atia Vision
Start Your
Free Trial Today
Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.




